Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. announced that the European Commission has approved the marketing authorization applications for two of its products, BILDYOS® and BILPREVDA®, for the treatment of osteoporosis and other bone-related conditions in the EU and EEA countries. This approval is based on extensive comparative studies demonstrating the similarity of HLX14 to the reference product, Prolia®, and marks a significant step in the company’s global expansion strategy, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, specializing in the development of biosimilar products. The company focuses on creating treatments for various medical conditions, including osteoporosis and cancer-related bone issues, and has a global market presence through partnerships.
Average Trading Volume: 1,469,333
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.27B
See more data about 2696 stock on TipRanks’ Stock Analysis page.